sitefansalaran International News

The global skin care industry is entering a decisive phase of structural transformation, where beauty is increasingly converging with long-term skin health and clinical performance. According to the latest strategic outlook by Future Market Insights (FMI), the global Rebalancing Skin Care Products Market—valued at USD 155.9 billion in 2026—is projected to reach USD 249.1 billion by 2036, expanding at a steady CAGR of 4.8% over the forecast period. The report highlights a fundamental industry pivot: rebalancing skin care is no longer positioned as a cosmetic enhancement category. Instead, it is becoming a mission-critical platform for barrier repair, inflammation control, and long-term skin resilience. Consumers are increasingly prioritizing preventive skin health, clinical credibility, and durability of results over short-term aesthetic correction, fundamentally reshaping product development and portfolio strategies across the global beauty ecosystem. The Rise of Science-Led, Portfolio-Rebalanced Skin Care A key driver of this decade-long expansion is the industry-wide move toward profitability-led growth and portfolio rationalization. Large beauty companies are actively reducing low-margin SKU proliferation and promotional dependency, instead concentrating capital on high-efficacy hero products and clinically positioned franchises that support pricing power and long-term consumer trust. “Where innovation comes in is that fusion with the health aspects of beauty – how do...

The Trump administration on Thursday launched TrumpRx, a website it says will help patients buy prescription drugs directly at a discounted rate at a time when health care and the cost of living are growing concerns for Americans. “You’re going to save a fortune,” President Donald Trump said at the site’s unveiling. “And this is also so good for overall health care.” The government-hosted website is not a platform for buying medications. Instead, it's set up as a facilitator, pointing Americans to drugmakers’ direct-to-consumer websites, where they can make purchases. It also provides coupons to use at pharmacies. The site launches with over 40 medications, including weight-loss drugs such as Ozempic and Wegovy. The site is part of a larger effort by the Trump administration to show it's tackling the challenges of high costs. Affordability has emerged as a political vulnerability for Trump and his Republican allies going into November's midterm elections, as Americans remain worried about the cost of housing, groceries, utilities and other staples of middle-class identity. The site is part of a larger effort by the Trump administration to show it's tackling the challenges of high costs. Affordability has emerged as a political vulnerability for Trump and his Republican allies...

Up to four in ten cancer cases worldwide could be prevented, according to a new global analysis from the World Health Organization (WHO) and its International Agency for Research on Cancer (IARC). The study examines 30 preventable causes, including tobacco, alcohol, high body mass index, physical inactivity, air pollution, ultraviolet radiation – and for the first time – nine cancer-causing infections. Released ahead of World Cancer Day, 4 February, the analysis estimates that 37% of all new cancer cases in 2022, around 7.1 million cases, were linked to preventable causes. The findings highlight the enormous potential of prevention in reducing the global cancer burden. Drawing on data from 185 countries and 36 cancer types, the study identifies tobacco as the leading preventable cause of cancer, globally responsible for 15% of all new cancer cases, followed by infections (10%) and alcohol consumption (3%). Three cancer types – lung, stomach and cervical cancer – accounted for nearly half of all preventable cancer cases in both men and women, globally. Lung cancer was primarily linked to smoking and air pollution, stomach cancer was largely attributable to Helicobacter pylori infection, and cervical cancer was overwhelmingly caused by human papillomavirus (HPV). “This is the first global analysis to show...

A hospital in Barcelona said ‌on ​Monday it had performed a ‌pioneering facial transplant in which the donor, in a world ​first, had offered her face for donation before undergoing an assisted dying procedure. The complex surgery ‍involved transplanting composite tissue from the ​central part of the face and required the participation of around 100 professionals, ​including psychiatrists ⁠and immunologists, the prestigious Vall d'Hebron hospital said in a statement. The hospital's transplant coordinator, Elisabeth Navas, said the donor had showed "a level of maturity that leaves one speechless". "Someone who has decided to end their life dedicates one of their last wishes to a ‌stranger and gives them a second chance of this magnitude," Navas said. GLOBAL LEADER ​IN ORGAN ‌TRANSPLANTS The recipient - identified only ‍by her ⁠first name Carme - had suffered facial tissue necrosis from a bacterial infection caused by an insect bite, affecting her ability to speak, eat and see. "When I'm looking in the mirror at home, I'm thinking that I'm starting to look more like myself," Carme told a press conference on Monday, adding her recovery was going very well. For such cases requiring facial transplants, donor ​and recipient must share the same sex, blood group and have a similar...

The Minister of Industry and Mineral Resources of the Kingdom of Saudi Arabia, Bandar Alkhorayef, has inaugurated the advanced pharmaceuticals factory Bpharma in Jeddah, marking a major milestone in the Kingdom’s growing pharmaceutical sector. The Bpharma project represents a major national initiative with an initial investment exceeding $120 million (SAR 450 million), which is expected to surpass $174 million (SAR 650 million) upon completion of its second phase, reflecting strong investor confidence and sustained growth potential in Saudi Arabia’s pharmaceutical sector. The project supports national efforts to localize drug manufacturing, strengthen supply chain efficiency, and enhance long-term health security across the Kingdom. The Bpharma factory spans approximately 38,000 square meters and adheres to the highest engineering and operational standards, incorporating full automation and advanced technologies to ensure high production efficiency, enhanced operational reliability, strict quality control compliance, and consistent output in line with international pharmaceutical regulations. This advanced pharmaceuticals factory features advanced production lines for sterile products, initially capable of producing 250 million units annually, with output expected to increase to over 450 million units in the second phase. Its product range includes critical care items, specialized medicines, as well as ophthalmic and respiratory products, catering to diverse healthcare needs across the Kingdom. The...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. In early 2024, the Big Pharma debuted a pair of unbranded shorts entitled “Big Night” and “Shame,” both of which focused on weight stigma. The former took aim at the off-label use of weight-loss meds by Hollywood stars and others who don’t have an actual medical need for the drugs, while the latter put the spotlight on the societal shame that lurks “like a shadow” for many people who are overweight or with obesity, ending with the message that “health is not about what weight we lose, it’s about all the things a body can gain.” Lilly is doubling down on that message in its newest film, “My Focus,” which debuted earlier this month and was made in partnership with Wieden+Kennedy Portland. Unlike its predecessors, which travel through different scenes and storylines, the new minute-long spot stays in a tight close-up on one person’s face the entire time. That choice was deliberate, in an effort to “reflect a more personal, lived experience with obesity and the real cultural pressures people face,” Lina Polimeni, Lilly’s chief consumer marketing officer, told Fierce Pharma...

Following a mercurial couple of years for biopharma M&A activity, 2025 saw a marked return to form, with a bevy of looming patent expirations and a thawing of the biotech investment scene prompting drug developers of all stripes to pull out their checkbooks in 2025. Still, the scope and scale of the deals tallied in 2025—which one leader at L.E.K. Consulting’s global health practices estimated to be the “strongest M&A year since 2019”—wasn’t a sure thing for much of the first half of 2025, as the industry grappled with major policy uncertainties in the U.S. But by the back half of the year, as the biopharma realm came to grips with the new normal, a spate of deals kicked off. 1-Johnson & Johnson and Intra-Cellular Deal value: $14.6 billion 2-Novartis and Avidity Deal value: $12 billion 3-Pfizer and Metsera Deal value: Up to $10 billion 4- Merck and Verona Deal value: $10 billion 5- Sanofi and Blueprint Deal value: Up to $9.5 billion 6- Thermo Fisher and Clario Deal value: Up to $9.4 billion 7- Merck and Cidara Deal value: $9.2 billion 8- enmab and Merus Deal value: $8 billion 9-Novo Nordisk and Akero Therapeutics Deal value: Up to $5.2 billion 10-Merck KGaA and SpringWorks Therapeutics Deal value: $3.9 billion

The World Health Organization (WHO) said it regrets that the U.S. has officially withdrawn from the U.N. health agency and it hopes Washington returns to active participation in the ⁠future. The U.S. left the organization on Thursday after a year of warnings that doing so would hurt public health in the U.S. and globally. President Donald Trump's administration has criticized the way the WHO handled the ⁠COVID-19 pandemic. Trump has said the WHO had failed to act independently from the "inappropriate political influence of WHO member states" and that the agency required "unfairly onerous payments" from the U.S. that were disproportionate to the sums provided by other, larger countries, such as China. WHO said it stands by its response to the "unprecedented global health crisis" brought about by the pandemic, adding that "the systems we developed and managed before, during and after the emergency phase of the pandemic, and which run 24/7, have contributed to keeping all countries safe, including the U.S."

SOHAR Port and Freezone has signed a land lease agreement with Pharma Investment Group, a joint venture between Omani investors and Algeria’s Spa IMGSA Group, to establish a pharmaceutical and medical supplies manufacturing facility within SOHAR Freezone. Spanning 40,000 sqm, this $20 million investment underscores SOHAR’s commitment to fostering a vibrant investment ecosystem that transforms trade in Oman through sustainable practices. With construction expected to commence in 2027, the new facility will be designed and built to meet the highest international standards, Good Manufacturing Practice (GMP) guidelines, and additional specialized international standards, including ISO 9001, and ISO 13485 certifications. The project will feature both sterile and non-sterile production lines, advanced Quality Control laboratories, and Research and Development units. Additionally, it will house a dedicated training center focused on developing national talent in pharmaceutical manufacturing and quality management. The project also includes the establishment of a comprehensive Research and Development Laboratory to drive innovation. Leveraging SPA IMGSA Group’s expertise as a GMP-certified leader in North Africa and Europe, the project will manufacture a diverse portfolio of healthcare products, including antibiotics, oncology treatments, medical gloves, sterile gauze, and medical consumables. This initiative will advance green manufacturing within SOHAR Freezone’s integrated framework, creating strong synergies in logistics,...

Wesam Medical Holding, a Saudi healthcare investment company, has announced the signing of a strategic Memorandum of Understanding (MOU) with McLaren Health Care, one of the largest healthcare systems in the state of Michigan, United States, and operator of the Karmanos Cancer Institute, to establish a specialized hematology and oncology hospital in Riyadh. Under the terms of the MOU, Wesam Medical Holding will oversee all legal, regulatory, and local market operations, while McLaren Health Care will be responsible for clinical, operational, and technical components, including hospital design and construction. This partnership marks a significant milestone in Saudi Arabia’s healthcare sector, representing McLaren’s entry into the Kingdom to provide comprehensive, integrated services for hematology and oncology patients. The collaboration will extend the reach of the system’s renowned Karmanos Cancer Institute, designated by the U.S. National Cancer Institute as a Comprehensive Cancer Center. The MOU was signed by Mr. Fahad Ibrahim Al-Khalaf, Chairman of Wesam Medical Holding Company, and Dr. Barton Buxton, President and Chief Executive Officer of McLaren Health Management Group, a subsidiary of McLaren Health Care. The partnership aims to transform oncology services in the Kingdom, aligning with the objectives of the Health Sector.